Form 8-K Galena Biopharma, Inc. For: Mar 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Roth Affirms Galena Biopharma (GALE) at 'Buy' Following Q4 Report; Still Sees FY15/FY16 as Busy Time Frame
March 6, 2015 8:42 AM ESTRoth Capital reiterates its Buy rating and $8 price target on Galena Biopharma (Nasdaq: GALE) following Q4, FY14 results reported Thursday night.
Analyst Joseph Pantginis noted that Galena's FY14 revenue of $9.32 million and loss of $0.31 per share compare with the firm's outlook calling for revenue of $8.5 million and loss of $0.35 per share.
Pantginis offered the following post-report commentary: 2015 represents a... More
Galena Biopharma (GALE) Reports Q4 Loss Per Share of 6c, Reiterates FY15 Rev. Guidance
March 5, 2015 4:21 PM ESTGalena Biopharma (NASDAQ: GALE) reported Q4 EPS of ($0.06), may not compare to the analyst estimate of ($0.11). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $2.58 million.
Galena reiterated 2015 net revenue guidance between $15-$18 million for the combined commercial... More
